Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906900 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis
A Phase 1 study of Spinal Metastasis, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06906900: Recruiting Phase 1 study of Spinal Metastasis, sponsored by M.D. Anderson Cancer Center.
NCT06906900 is a Phase 1 study of Spinal Metastasis that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06906900, a Phase 1 study of Spinal Metastasis, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical research study is to learn about the safety of the NovoTTF-200M and Novo TTF-200A Systems, when used either alone or in combination with standard therapy, in patients with tumors that did not respond to treatment.
Conditions Studied
Interventions
- DEVICE TTF-200M and TTF-200A systems
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2029-02-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06906900
The ClinicalTrials.gov registry entry for NCT06906900 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Spinal Metastasis appearing as the primary indexed condition, and to 1 intervention - of which TTF-200M and TTF-200A systems is the first listed.
NCT06906900 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06906900 about?
NCT06906900 is a clinical study titled "A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis". This clinical research study is to learn about the safety of the NovoTTF-200M and Novo TTF-200A Systems, when used either alone or in combination with standard therapy, in patients with tumors that did not respond to treatment.
What is the current status of trial NCT06906900?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-08-18. Estimated completion is 2029-02-17.
What conditions does trial NCT06906900 study?
This clinical trial studies the following conditions: Spinal Metastasis.
What interventions are being tested in trial NCT06906900?
The interventions under investigation include: TTF-200M and TTF-200A systems (DEVICE).
Who is sponsoring clinical trial NCT06906900?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06906900 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.